Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Medication Side Effect Clear all
Active, not recruiting No phase listed Observational

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

NCT05036252
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 10, 2026, 10:01 AM EDT
Terminated Phase 1 Interventional

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

NCT00238173
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jun 10, 2026, 10:01 AM EDT
Completed No phase listed Observational

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887
View directory record Official record
Conditions
Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
73
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 10, 2026, 10:01 AM EDT
Completed Phase 2 Interventional

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

NCT00034021
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions
Ginkgo Biloba, Sex Therapy (genital focus)
Drug · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jun 10, 2026, 10:01 AM EDT
Recruiting Phase 3 Interventional

Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

NCT06303128
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Amoxicillin 250 MG, Placebo, Amoxicillin 62.5mg, Amoxicillin 187.5mg
Drug
Lead sponsor
James Tarbox, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jun 10, 2026, 10:01 AM EDT
Completed Phase 3 Interventional

Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

NCT00017004
View directory record Official record
Conditions
Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Drug Toxicity, Radiation Toxicity, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions
External Beam Radiation Therapy, Cisplatin, Internal Radiation Therapy, Epoetin Alfa
Radiation · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Jun 10, 2026, 10:01 AM EDT
Active, not recruiting Not applicable Interventional

Telehealth and Memory Study

NCT04586530
View directory record Official record
Conditions
Chemotherapy-related Cognitive Dysfunction
Interventions
Memory and Attention Adaptation Training (MAAT), Supportive Therapy (ST)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 10, 2026, 10:01 AM EDT
Completed Phase 2 Interventional

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

NCT00055718
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
silymarin
Dietary Supplement
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
2 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
7
States / cities
Miami, Florida • Mineola, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jun 10, 2026, 10:01 AM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

NCT00004036
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, carboplatin, cyclophosphamide
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Jun 10, 2026, 10:01 AM EDT
Terminated Phase 4 Interventional Results available

Post-operative Pain Control After Pediatric Adenotonsillectomy

NCT02296840
View directory record Official record
Conditions
Recurrent Tonsillitis, Obstructive Sleep Apnea, Sleep Disordered Breathing, Adverse Reaction to Drug
Interventions
Ibuprofen, Hydrocodone-Acetaminophen
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Jun 10, 2026, 10:01 AM EDT
Terminated Phase 3 Interventional

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

NCT00092287
View directory record Official record
Conditions
Malignant Carcinoid Syndrome
Interventions
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Jun 10, 2026, 10:01 AM EDT
Completed Not applicable Interventional

Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients

NCT03324945
View directory record Official record
Conditions
Chemotherapy-induced Cognitive Impairment
Interventions
Neurocognitive assessments
Behavioral
Lead sponsor
Rachel Miller
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Jun 10, 2026, 10:01 AM EDT
Completed Not applicable Interventional

Personal Health Records and Elder Medication Use Quality

NCT02012712
View directory record Official record
Conditions
Adverse Reaction to Drug, Health Behavior, Medication Adherence, Physician-Patient Relations
Interventions
Personal Health Record (PHR)
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
65 Years to 95 Years
Enrollment
1,163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 10, 2026, 10:01 AM EDT
Not listed No phase listed Observational

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

NCT02081872
View directory record Official record
Conditions
Genetics of Drug Metabolism
Interventions
Not listed
Lead sponsor
Companion Dx Reference Lab, LLC
Industry
Eligibility
18 Years and older
Enrollment
279,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Scottsdale, Arizona • Augusta, Arkansas • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Jun 10, 2026, 10:01 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

NCT01256489
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Corneal Blindness
Interventions
Infliximab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jun 10, 2026, 10:01 AM EDT
Completed No phase listed Observational

Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study

NCT04361240
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity
Interventions
Proton vs Photon Radiation
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 10, 2026, 10:01 AM EDT
Completed No phase listed Observational

Response to Medication Registry

NCT02593916
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jun 10, 2026, 10:01 AM EDT
Recruiting Not applicable Interventional

Serious Gaming for Chemotherapy-induced Nausea and Vomiting

NCT05838638
View directory record Official record
Conditions
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Interventions
eSSET-CINV
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
60 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 10, 2026, 10:01 AM EDT
Completed Phase 2 Interventional

Statewide Implementation of Electronic Health Records

NCT00225576
View directory record Official record
Conditions
Medication Errors
Interventions
Electronic Health Record Implementation
Other
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jun 10, 2026, 10:01 AM EDT
Terminated Phase 2 Interventional Results available

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

NCT00090844
View directory record Official record
Conditions
Breast Cancer, Hormone Changes, Drug Toxicity
Interventions
triptorelin
Drug
Lead sponsor
University of South Florida
Other
Eligibility
Up to 44 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
9
States / cities
Oakland, California • Tampa, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jun 10, 2026, 10:01 AM EDT
Completed No phase listed Observational

Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy

NCT04036032
View directory record Official record
Conditions
Cancer, Cardiotoxicity
Interventions
Exercise program
Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
9 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Hartford, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 10, 2026, 10:01 AM EDT
Completed No phase listed Observational

Cytokines Polymorphisms and Acetaminophen Toxicity

NCT00166608
View directory record Official record
Conditions
Drug Toxicity
Interventions
Blood sampling
Procedure
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Not listed
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Little Rock, Arkansas • Louisville, Kentucky • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Jun 10, 2026, 10:01 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

NCT02119091
View directory record Official record
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jun 10, 2026, 10:01 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Novel On-body Evaluation of Cardiac Health for Oncology

NCT07158450
View directory record Official record
Conditions
Cardiotoxicity, Heart Failure
Interventions
Not listed
Lead sponsor
Skribe Medical
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Golden, Colorado • Clearwater, Florida • Naperville, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 10:01 AM EDT